Carregant...
Moxetumomab pasudotox: clinical experience in relapsed/refractory hairy cell leukemia
BACKGROUND: Moxetumomab pasudotox is a promising new therapy for the treatment of patients with relapsed/refractory hairy cell leukemia (R/R HCL), but practical guidance relating to its administration is limited. OBJECTIVES: To describe the authors’ experience of administering moxetumomab pasudotox...
Guardat en:
| Publicat a: | Clin J Oncol Nurs |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6688475/ https://ncbi.nlm.nih.gov/pubmed/31099793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1188/19.CJON.E52-E59 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|